Larval application of sodium channel homologous dsRNA restores pyrethroid insecticide susceptibility in a resistant adult mosquito population

Bona, Ana Caroline Dalla; Chitolina, Rodrigo Faitta; Fermino, Marise Lopes; Poncio, Lisiane de Castro; Weiss, Avital; Lima, José Bento Pereira; Paldi, Nitzan; Bernardes, Emerson Soares; Henen, Jonathan; Maori, Eyal.
Artículo en Inglés | ARCA | ID: arc-15281

Documentos relacionados

  1. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications.
  2. Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.
  3. Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria.
  4. A New Approach to PCSK9 Therapeutics.
  5. Re: An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
  6. Novel RNAi-Based Therapies for Atherosclerosis.
  7. RNAi Arrives at the Bedside after a Mere Two Decades.
  8. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
  9. Acyclic (<i>S</i>)-glycol nucleic acid (<i>S</i>-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency.
  10. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.